Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.140
+0.040 (3.64%)
At close: Jul 21, 2026, 4:00 PM EDT
1.140
0.00 (0.00%)
After-hours: Jul 21, 2026, 4:10 PM EDT
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Lineage Cell Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.50. The average 1-year stock price forecast is 382.46% higher than the current stock price, while the lowest is $3.00 (+163.16%) and the highest is $9.00 (+689.47%).
Price Target: $5.50 (+382.46%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $9 | Buy | Reiterates | $9 | +689.47% | Jul 14, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $3 | Buy | Maintains | $3 | +163.16% | May 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $9 | Buy | Maintains | $9 | +689.47% | May 13, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $3 → $4 | Buy | Maintains | $3 → $4 | +250.88% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
17.94M
from 14.56M
Increased by 23.27%
Revenue Next Year
18.14M
from 17.94M
Increased by 1.11%
EPS This Year
-0.07
from -0.22
EPS Next Year
-0.09
from -0.07
EPS and Forward PE are based on non-GAAP adjusted numbers.